Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial

Title
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial
Author(s)
이형우B. Y. Cha[B. Y. Cha]M. K. Kim[M. K. Kim]E.-J, Rhee[E.-J, Rhee]B. J. Ku[ B. J. Ku]C. H. Chung[C. H. Chung]K. A. Kim[K. A. Kim]I. B. Park[I. B. Park]J. Y. Park [J. Y. Park ]K. S, Park[K. S, Park]
Keywords
COMBINATION THERAPY; JAPANESE PATIENTS; GLUCOSE CONTROL; METAANALYSIS
Issue Date
201503
Publisher
WILEY-BLACKWELL
Citation
DIABETES OBESITY & METABOLISM, v.17, no.3, pp.309 - 312
Abstract
The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin (HbA1c) 7.0-10.0%, on stable metformin >= 1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin (n=136) or placebo plus metformin (n=68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were -0.78 % and -1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes.
URI
http://hdl.handle.net/YU.REPOSITORY/33244http://dx.doi.org/10.1111/dom.12424
ISSN
1462-8902
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE